BRPI0510044A - composição farmacêutica, kit, método para tratar um indivìduo, e, uso de uma primeira e uma segunda quantidade de um ou mais glicocorticóides - Google Patents

composição farmacêutica, kit, método para tratar um indivìduo, e, uso de uma primeira e uma segunda quantidade de um ou mais glicocorticóides

Info

Publication number
BRPI0510044A
BRPI0510044A BRPI0510044-5A BRPI0510044A BRPI0510044A BR PI0510044 A BRPI0510044 A BR PI0510044A BR PI0510044 A BRPI0510044 A BR PI0510044A BR PI0510044 A BRPI0510044 A BR PI0510044A
Authority
BR
Brazil
Prior art keywords
glucocorticoids
pharmaceutical composition
glucocorticoid
individual
treating
Prior art date
Application number
BRPI0510044-5A
Other languages
English (en)
Inventor
Stanko Skrtic
Joergen Johnsson
Hans Lennernos
Thomas Hedner
Gudmundur Johannsson
Original Assignee
Duocort Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duocort Ab filed Critical Duocort Ab
Publication of BRPI0510044A publication Critical patent/BRPI0510044A/pt
Publication of BRPI0510044B1 publication Critical patent/BRPI0510044B1/pt
Publication of BRPI0510044B8 publication Critical patent/BRPI0510044B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Abstract

COMPOSIçãO FARMACêUTICA, KIT, MéTODO PARA TRATAR UM INDIVìDUO, E, USO DE UMA PRIMEIRA E UMA SEGUNDA QUANTIDADE DE UM OU MAIS GLICOCORTICóIDES. A invenção refere-se a terapia de substituição de glicocorticóide e fornece composições farmacêuticas e kits projetados para suprir um ou mais glicocorticóides a um indivíduo em necessidade deles, de uma maneira que resulte em níveis de soro de glicocorticóide que essencialmente imitam aqueles de um indivíduo saudável, por um período de tempo clinicamente relevante. A composição farmacêutica compreende um ou mais glicocorticóides, em que uma primeira parte de um ou mais glicocorticóides é substancial e imediatamente liberada durante um período prolongado de tempo de pelo menos cerca de 8 horas, e a quantidade do um ou mais glicocorticóides da primeira parte, expressa como equivalentes de hidrocortisona, está em uma faixa de cerca de 15 a cerca de 50% dos equivalentes totais de hidrocortisona. A invenção também refere-se a um método de tratar doenças requerendo tratamento por glicocorticóide, tal como em indivíduos tendo um distúrbio de deficiência de glicocorticóide. Em outro aspecto, a invenção refere-se ao uso de uma primeira e uma segunda quantidade de um ou mais glicocorticóides, para a preparação de uma composição farmacêutica ou kit para o tratamento de um distúrbio de deficiência de glicocorticóide.
BRPI0510044A 2004-04-22 2005-04-21 composição farmacêutica, e, uso de uma composição farmacêutica BRPI0510044B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56420504P 2004-04-22 2004-04-22
SE0401031A SE0401031D0 (sv) 2004-04-22 2004-04-22 A new glucocorticoid replacement therapy
PCT/EP2005/004400 WO2005102271A2 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy

Publications (3)

Publication Number Publication Date
BRPI0510044A true BRPI0510044A (pt) 2007-10-16
BRPI0510044B1 BRPI0510044B1 (pt) 2019-01-29
BRPI0510044B8 BRPI0510044B8 (pt) 2021-05-25

Family

ID=35197481

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510044A BRPI0510044B8 (pt) 2004-04-22 2005-04-21 composição farmacêutica, e, uso de uma composição farmacêutica

Country Status (26)

Country Link
US (3) US8425937B2 (pt)
EP (2) EP3072507B1 (pt)
JP (2) JP5149618B2 (pt)
CN (2) CN103006592B (pt)
AU (1) AU2005235370B2 (pt)
BR (1) BRPI0510044B8 (pt)
CA (1) CA2564000C (pt)
CY (2) CY1118275T1 (pt)
DK (2) DK1744730T3 (pt)
ES (2) ES2600556T3 (pt)
HK (1) HK1179525A1 (pt)
HR (2) HRP20161380T1 (pt)
HU (2) HUE053248T2 (pt)
IL (2) IL178776A (pt)
LT (2) LT1744730T (pt)
ME (1) ME02584B (pt)
MX (2) MXPA06012011A (pt)
NZ (1) NZ585340A (pt)
PL (2) PL1744730T3 (pt)
PT (2) PT3072507T (pt)
RS (2) RS61501B1 (pt)
SE (1) SE0401031D0 (pt)
SG (1) SG188081A1 (pt)
SI (1) SI3072507T1 (pt)
WO (1) WO2005102271A2 (pt)
ZA (1) ZA200609680B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2563609C (en) * 2004-04-22 2012-11-06 Duocort Ab Pharmaceutical compositions for acute glucocorticoid therapy
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
AU2006322050A1 (en) * 2005-12-06 2007-06-14 Monosol Rx, Llc Topical film compositions for delivery of actives
FR2926722B1 (fr) * 2008-01-25 2010-09-03 Substipharm Dev Formulation pharmaceutique appropriee pour la preparation de comprimes orodispersibles de prednisolone
RS51649B (en) * 2008-07-21 2011-10-31 Dr. Falk Pharma Gmbh. PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF THE UPPER DIGESTIVE TRACT
EP2416783B1 (en) 2009-04-07 2018-11-07 Shire Viropharma Incorporated Improved glucocorticoid therapy
BR112012029466A2 (pt) * 2010-05-20 2017-03-01 Duocort Phama Ab "composição de glicocorticoide, método melhorado para tratar a deficiência de glicocorticoide, e, método para dar origem a uma dosagem individualizada de glicocorticoides"
GB201119985D0 (en) * 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201202433D0 (en) * 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
JP2014086673A (ja) 2012-10-26 2014-05-12 Mitsubishi Electric Corp モノリシック集積回路
NZ747657A (en) 2012-11-02 2019-12-20 Murray And Poole Entpr Ltd Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
MY198452A (en) 2013-04-16 2023-08-29 Murray And Poole Enterprises Ltd Sustained-release formulations of colchicine and methods of using same
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
MX348595B (es) * 2013-08-02 2017-06-21 Laboratorio Raam De Sahuayo S A De C V Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion.
EP2886108B2 (de) 2013-12-23 2022-11-02 Dr. Falk Pharma Gmbh Optimierte pharmazeutische Formulierung zur Behandlung von entzündlichen Veränderungen des Ösophagus
JP6754533B2 (ja) 2015-03-30 2020-09-16 コーセプト セラピューティクス， インコーポレイテッド 副腎機能不全を処置するための糖質コルチコイドと組み合わせた糖質コルチコイドレセプターアンタゴニストの使用
CN107115308B (zh) * 2016-02-23 2021-02-23 天津金耀集团有限公司 一种氢化可的松双相缓释片剂组合物
RU2748437C2 (ru) * 2019-10-28 2021-05-25 Федеральное государственное бюджетное учреждение науки Институт цитологии Российской академии наук (ИНЦ РАН) Производное гидрокортизона в качестве средства для лечения болезни Альцгеймера
FR3116439B1 (fr) * 2020-11-26 2023-08-04 Laboratoire Dielen Comprimé pelliculé contenant au moins un principe actif, adapté à l’administration par voie orale dudit au moins un principe actif chez des sujets humains

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2260384C3 (de) * 1972-12-09 1979-11-29 Hoechst Ag, 6000 Frankfurt Oral zu applizierendes Corticosteroid-Präparat
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5314697A (en) 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
CA2179382C (en) 1994-01-31 2009-11-10 Takao Mizumoto Intrabuccally dissolving compressed moldings and production process thereof
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
DE19718012C1 (de) * 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6156743A (en) 1999-10-18 2000-12-05 Whitcomb; John E. Method of decreasing fatigue
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
US20030190360A1 (en) 2001-03-13 2003-10-09 Baichwal Anand R. Chronotherapeutic dosage forms containing glucocorticosteroid and methods of treatment
JP2005508836A (ja) * 2001-03-15 2005-04-07 エンテロン ファーマシューティカルズ インコーポレーティッド 局所作用性コルチコステロイドを用いる胃腸管の炎症性疾患の治療方法
GB0119848D0 (en) 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
DE60308647T2 (de) 2002-02-07 2007-08-09 Pharmacia Corp. Pharmazeutische darreichungsform zur mukosalen verabreichung
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
CA2563609C (en) 2004-04-22 2012-11-06 Duocort Ab Pharmaceutical compositions for acute glucocorticoid therapy
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
GB0623740D0 (en) 2006-11-28 2007-01-10 Diurnal Ltd Treatment of disease
EP2416783B1 (en) 2009-04-07 2018-11-07 Shire Viropharma Incorporated Improved glucocorticoid therapy
BR112012029466A2 (pt) 2010-05-20 2017-03-01 Duocort Phama Ab "composição de glicocorticoide, método melhorado para tratar a deficiência de glicocorticoide, e, método para dar origem a uma dosagem individualizada de glicocorticoides"

Also Published As

Publication number Publication date
IL227375A (en) 2017-08-31
EP3072507A1 (en) 2016-09-28
HUE053248T2 (hu) 2021-06-28
JP5681679B2 (ja) 2015-03-11
IL178776A0 (en) 2007-02-11
EP3072507B1 (en) 2020-12-23
CA2564000A1 (en) 2005-11-03
CY1124074T1 (el) 2022-03-24
HRP20161380T1 (hr) 2016-12-02
US20080187586A1 (en) 2008-08-07
HRP20210348T1 (hr) 2021-04-16
AU2005235370A1 (en) 2005-11-03
RS55198B1 (sr) 2017-01-31
JP2007533698A (ja) 2007-11-22
CN1942176B (zh) 2013-09-18
IL178776A (en) 2013-10-31
SI3072507T1 (sl) 2021-04-30
CY1118275T1 (el) 2017-06-28
DK1744730T3 (en) 2016-08-29
ME02584B (me) 2017-06-20
HK1179525A1 (zh) 2013-10-04
NZ585340A (en) 2012-04-27
US8425937B2 (en) 2013-04-23
EP1744730A2 (en) 2007-01-24
RS61501B1 (sr) 2021-03-31
PL1744730T3 (pl) 2017-01-31
US20140242167A1 (en) 2014-08-28
MXPA06012011A (es) 2007-04-16
CN103006592B (zh) 2016-03-02
EP1744730B1 (en) 2016-08-03
CA2564000C (en) 2013-07-02
ES2857600T3 (es) 2021-09-29
DK3072507T3 (da) 2021-02-08
WO2005102271A3 (en) 2006-08-03
ES2600556T3 (es) 2017-02-09
JP2012236846A (ja) 2012-12-06
BRPI0510044B1 (pt) 2019-01-29
CN1942176A (zh) 2007-04-04
WO2005102271A2 (en) 2005-11-03
LT3072507T (lt) 2021-02-25
PL3072507T3 (pl) 2021-07-19
BRPI0510044B8 (pt) 2021-05-25
PT3072507T (pt) 2021-02-23
JP5149618B2 (ja) 2013-02-20
CN103006592A (zh) 2013-04-03
HUE030546T2 (en) 2017-05-29
MX344197B (es) 2016-12-08
US20130129823A1 (en) 2013-05-23
SE0401031D0 (sv) 2004-04-22
SG188081A1 (en) 2013-03-28
PT1744730T (pt) 2016-10-07
AU2005235370B2 (en) 2011-06-09
LT1744730T (lt) 2016-10-25
US10583146B2 (en) 2020-03-10
ZA200609680B (en) 2008-08-27

Similar Documents

Publication Publication Date Title
BRPI0510044A (pt) composição farmacêutica, kit, método para tratar um indivìduo, e, uso de uma primeira e uma segunda quantidade de um ou mais glicocorticóides
Matarese et al. Transglutaminase 2 up-regulation is associated with RANKL/OPG pathway in cultured HPDL cells and THP-1-differentiated macrophages
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
Sonoda et al. Exogenous nitric oxide stimulates the odontogenic differentiation of rat dental pulp stem cells
BR0307871A (pt) Proteìnas contendo domìnio de folistatina
ATE529125T1 (de) Pharmazeutische zusammensetzungen und verfahren zur beschleunigung der wundheilung
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
Wang et al. Mineral trioxide aggregate enhances the osteogenic capacity of periodontal ligament stem cells via NF‐κB and MAPK signaling pathways
BRPI0411295A (pt) compostos e seu uso na terapia
BRPI0516105A (pt) composições de fator de crescimento derivado de plaqueta e métodos de uso destas
BRPI0409678A (pt) métodos para identificar um composto, para tratar ou prevenir uma doença ou distúrbio em um humano, para incrementar a função de órgãos, tecidos, ou células excitáveis em um humano e para modular a atividade de um complexo de receptores de citocinas protetor de tecidos em um humano
CL2007001388A1 (es) Co-cristal de maleato de 2{etil[3-({4-[(5-{2-[(3-fluorfenil)amino]-2-oxoetil}-1h-pirazol-3-il)amino]quinazolin-7-il}oxi)propil]amino}fosfato dihidrogeno de etilo (azd1152), inhibidor de aurora quinasa; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades hiperproliferativas como el cancer.
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
BR0213817A (pt) Tratamento de sìndrome de resistência à insulina e diabete do tipo 2 com inibidores da pde9
Nasi et al. The protective role of the 3-mercaptopyruvate sulfurtransferase (3-MST)-hydrogen sulfide (H 2 S) pathway against experimental osteoarthritis
de Campos et al. Smoking modulates gene expression of type I collagen, bone sialoprotein, and osteocalcin in human alveolar bone
DE69637556D1 (de) Sulfat-Konjugate der Ursodeoxycholsäure und deren nützliche Verwendung bei entzündlichen Erkrankungen und anderen Anwendungen
BRPI0418973A (pt) composições de risedronato e seus métodos de uso
Carmody et al. Folic acid inhibits homocysteine-induced proliferation of human arterial smooth muscle cells
BR0107721A (pt) Combinação, uso de mirtapazina e gepirona, método para o tratamento de depressão ou de um distúrbio relacionado em um indivìduo de uma espécie vertebrada, e, kit de paciente que contém meios para a administração de doses unitárias dosadas
Yıldırım et al. The effects of metformin on the bone filling ration around of TiAl6Va4 implants in non diabetic rats
Chou et al. Culturing and characterization of human periodontal ligament fibroblasts—a preliminary study
Yoon et al. Differential effects of two protein tyrosine kinase inhibitors, tyrphostin and genistein, on human bone cell proliferation as compared with differentiation
BR0309406A (pt) Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/04/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF